{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:29:53Z","timestamp":1790515793497,"version":"4.1.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Erythroferrone (ERFE) is produced by erythroblasts in response to erythropoietin (EPO) and acts in the liver to prevent hepcidin stimulation by BMP6. Hepcidin suppression allows for the mobilization of iron to the bone marrow for the production of red blood cells. Aberrantly high circulating ERFE in conditions of stress erythropoiesis, such as in patients with \u03b2-thalassemia, promotes the tissue iron accumulation that substantially contributes to morbidity in these patients. Here we developed antibodies against ERFE to prevent hepcidin suppression and to correct the iron loading phenotype in a mouse model of \u03b2-thalassemia [Hbb(th3\/+) mice] and used these antibodies as tools to further characterize ERFE\u2019s mechanism of action. We show that ERFE binds to BMP6 with nanomolar affinity and binds BMP2 and BMP4 with somewhat weaker affinities. We found that BMP6 binds the N-terminal domain of ERFE, and a polypeptide derived from the N terminus of ERFE was sufficient to cause hepcidin suppression in Huh7 hepatoma cells and in wild-type mice. Anti-ERFE antibodies targeting the N-terminal domain prevented hepcidin suppression in ERFE-treated Huh7 cells and in EPO-treated mice. Finally, we observed a decrease in splenomegaly and serum and liver iron in anti\u2013ERFE-treated Hbb(th3\/+) mice, accompanied by an increase in red blood cells and hemoglobin and a decrease in reticulocyte counts. In summary, we show that ERFE binds BMP6 directly and with high affinity, and that antibodies targeting the N-terminal domain of ERFE that prevent ERFE\u2013BMP6 interactions constitute a potential therapeutic tool for iron loading anemias.<\/jats:p>","DOI":"10.1182\/blood.2019003140","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T20:53:20Z","timestamp":1578084800000},"page":"547-557","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4214-7337","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Arezes","sequence":"first","affiliation":[{"name":"MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall","family":"Foy","sequence":"first","affiliation":[{"name":"BioMedicine Design, Pfizer Biotherapeutics R&D, Dublin, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"McHugh","sequence":"first","affiliation":[{"name":"Jenner Institute, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Quinkert","sequence":"first","affiliation":[{"name":"Jenner Institute, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Benard","sequence":"first","affiliation":[{"name":"BioMedicine Design, Pfizer Biotherapeutics R&D, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anagha","family":"Sawant","sequence":"first","affiliation":[{"name":"Rare Disease Research Unit, Pfizer Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe N.","family":"Frost","sequence":"first","affiliation":[{"name":"MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-6602","authenticated-orcid":false,"given":"Andrew E.","family":"Armitage","sequence":"first","affiliation":[{"name":"MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5502-0434","authenticated-orcid":false,"given":"Sant-Rayn","family":"Pasricha","sequence":"first","affiliation":[{"name":"MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom;"},{"name":"Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia;"},{"name":"Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Jin","family":"Lim","sequence":"first","affiliation":[{"name":"MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May S.","family":"Tam","sequence":"first","affiliation":[{"name":"Rare Disease Research Unit, Pfizer Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lavallie","sequence":"first","affiliation":[{"name":"Rare Disease Research Unit, Pfizer Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra D.","family":"Pittman","sequence":"first","affiliation":[{"name":"Rare Disease Research Unit, Pfizer Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Cunningham","sequence":"first","affiliation":[{"name":"BioMedicine Design, Pfizer Biotherapeutics R&D, Dublin, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lambert","sequence":"first","affiliation":[{"name":"BioMedicine Design, Pfizer Biotherapeutics R&D, Dublin, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Murphy","sequence":"first","affiliation":[{"name":"Rare Disease Research Unit, Pfizer Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-1357","authenticated-orcid":false,"given":"Simon J.","family":"Draper","sequence":"first","affiliation":[{"name":"Jenner Institute, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Jasuja","sequence":"first","affiliation":[{"name":"Rare Disease Research Unit, Pfizer Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8503-6103","authenticated-orcid":false,"given":"Hal","family":"Drakesmith","sequence":"first","affiliation":[{"name":"MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom;"},{"name":"Haematology Theme NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"13","key":"2020022011594555600_B1","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2010-08-300335","article-title":"How I treat thalassemia","volume":"118","author":"Rachmilewitz","year":"2011","journal-title":"Blood"},{"issue":"10116","key":"2020022011594555600_B2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"2020022011594555600_B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0950-3536(98)80069-3","article-title":"The population genetics of the haemoglobinopathies","volume":"11","author":"Flint","year":"1998","journal-title":"Baillieres Clin Haematol"},{"issue":"7","key":"2020022011594555600_B4","doi-asserted-by":"crossref","first-page":"a013482","DOI":"10.1101\/cshperspect.a013482","article-title":"\u03b2-thalassemia intermedia: a clinical perspective","volume":"2","author":"Musallam","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"2020022011594555600_B5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s12185-016-1991-5","article-title":"Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors","volume":"103","author":"Tantiworawit","year":"2016","journal-title":"Int J Hematol"},{"issue":"3-4","key":"2020022011594555600_B6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcmd.2012.06.001","article-title":"Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with \u03b2-thalassemia intermedia","volume":"49","author":"Musallam","year":"2012","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"2020022011594555600_B7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2010.08180.x","article-title":"Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience","volume":"150","author":"Restivo Pantalone","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2020022011594555600_B8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4254\/wjh.v2.i5.171","article-title":"Hepatocellular carcinoma in thalassemia: a critical review","volume":"2","author":"Mancuso","year":"2010","journal-title":"World J Hepatol"},{"issue":"11","key":"2020022011594555600_B9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3324\/haematol.2011.047852","article-title":"Elevated liver iron concentration is a marker of increased morbidity in patients with \u03b2 thalassemia intermedia","volume":"96","author":"Musallam","year":"2011","journal-title":"Haematologica"},{"key":"2020022011594555600_B10","first-page":"197","article-title":"Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions","volume":"6","author":"Saliba","year":"2015","journal-title":"J Blood Med"},{"issue":"1","key":"2020022011594555600_B11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-nutr-071715-050731","article-title":"Regulation of hepcidin by erythropoiesis: the story so far","volume":"36","author":"Pasricha","year":"2016","journal-title":"Annu Rev Nutr"},{"issue":"5704","key":"2020022011594555600_B12","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"issue":"8","key":"2020022011594555600_B13","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2017-05-786590","article-title":"Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin","volume":"131","author":"Aschemeyer","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2020022011594555600_B14","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1182\/blood-2006-09-048868","article-title":"Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin","volume":"109","author":"Gardenghi","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2020022011594555600_B15","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ng.335","article-title":"BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism","volume":"41","author":"Andriopoulos","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"2020022011594555600_B16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ng.320","article-title":"Lack of the bone morphogenetic protein BMP6 induces massive iron overload","volume":"41","author":"Meynard","year":"2009","journal-title":"Nat Genet"},{"key":"2020022011594555600_B17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cytogfr.2015.11.005","article-title":"Structural insights into BMP receptors: specificity, activation and inhibition","volume":"27","author":"Yadin","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"2020022011594555600_B18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s42255-019-0063-6","article-title":"Nrf2 controls iron homeostasis in haemochromatosis and thalassaemia via Bmp6 and hepcidin","volume":"1","author":"Lim","year":"2019","journal-title":"Nat Metab"},{"issue":"4","key":"2020022011594555600_B19","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1182\/blood-2008-03-143354","article-title":"Iron regulates phosphorylation of Smad1\/5\/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver","volume":"112","author":"Kautz","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2020022011594555600_B20","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/ajh.24888","article-title":"Bone morphogenetic protein 2 controls iron homeostasis in mice independent of Bmp6","volume":"92","author":"Canali","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"2020022011594555600_B21","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"2020022011594555600_B22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood-2016-12-759423","article-title":"Smad1\/5 is required for erythropoietin-mediated suppression of hepcidin in mice","volume":"130","author":"Wang","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2020022011594555600_B23","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/ajh.24672","article-title":"Erythroferrone and matriptase-2 independently regulate hepcidin expression","volume":"92","author":"Aschemeyer","year":"2017","journal-title":"Am J Hematol"},{"issue":"14","key":"2020022011594555600_B24","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","article-title":"Erythroferrone inhibits the induction of hepcidin by BMP6","volume":"132","author":"Arezes","year":"2018","journal-title":"Blood"},{"issue":"17","key":"2020022011594555600_B25","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2015-07-658419","article-title":"Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of \u03b2-thalassemia","volume":"126","author":"Kautz","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2020022011594555600_B26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood-2017-04-777987","article-title":"Immunoassay for human serum erythroferrone","volume":"130","author":"Ganz","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020022011594555600_B27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","article-title":"Minihepcidin peptides as disease modifiers in mice affected by \u03b2-thalassemia and polycythemia vera","volume":"128","author":"Casu","year":"2016","journal-title":"Blood"},{"key":"2020022011594555600_B28","article-title":"Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult beta-thalassemia major [published online ahead of print October 3, 2019]","author":"Casu","journal-title":"Haematologica"},{"issue":"23","key":"2020022011594555600_B29","doi-asserted-by":"crossref","first-page":"16529","DOI":"10.1074\/jbc.M113.457689","article-title":"Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics","volume":"288","author":"Ishino","year":"2013","journal-title":"J Biol Chem"},{"key":"2020022011594555600_B30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/978-1-60761-913-0_21","article-title":"Optimized generation of high-affinity, high-specificity single-chain Fv antibodies from multiantigen immunized chickens","volume":"681","author":"Finlay","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"7","key":"2020022011594555600_B31","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1074\/jbc.M111023200","article-title":"Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter","volume":"277","author":"Korchynskyi","year":"2002","journal-title":"J Biol Chem"},{"issue":"3","key":"2020022011594555600_B32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jmb.2009.03.019","article-title":"Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions","volume":"388","author":"Finlay","year":"2009","journal-title":"J Mol Biol"},{"issue":"1","key":"2020022011594555600_B33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1875397300903010022","article-title":"HTRF: a technology tailored for drug discovery\u2014a review of theoretical aspects and recent applications","volume":"3","author":"Degorce","year":"2009","journal-title":"Curr Chem Genomics"},{"issue":"6","key":"2020022011594555600_B34","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V84.6.1697.1697","article-title":"Regulators of iron balance in humans","volume":"84","author":"Finch","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2020022011594555600_B35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3324\/haematol.2014.114827","article-title":"\u03b2-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies","volume":"100","author":"Rivella","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"2020022011594555600_B36","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1172\/JCI66969","article-title":"Reducing TMPRSS6 ameliorates hemochromatosis and \u03b2-thalassemia in mice","volume":"123","author":"Guo","year":"2013","journal-title":"J Clin Invest"},{"issue":"7","key":"2020022011594555600_B37","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood-2012-09-453977","article-title":"An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-\/-) mice and ameliorates anemia and iron overload in murine \u03b2-thalassemia intermedia","volume":"121","author":"Schmidt","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2020022011594555600_B38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nm.2073","article-title":"Transferrin therapy ameliorates disease in beta-thalassemic mice","volume":"16","author":"Li","year":"2010","journal-title":"Nat Med"},{"issue":"12","key":"2020022011594555600_B39","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1172\/JCI41717","article-title":"Hepcidin as a therapeutic tool to limit iron overload and improve anemia in \u03b2-thalassemic mice","volume":"120","author":"Gardenghi","year":"2010","journal-title":"J Clin Invest"},{"issue":"1","key":"2020022011594555600_B40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2141.2003.04734.x","article-title":"Decreased hepcidin mRNA expression in thalassemic mice","volume":"124","author":"Adamsky","year":"2004","journal-title":"Br J Haematol"},{"issue":"5","key":"2020022011594555600_B41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3324\/haematol.10842","article-title":"Liver iron concentrations and urinary hepcidin in beta-thalassemia","volume":"92","author":"Origa","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"2020022011594555600_B42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/pbc.20616","article-title":"Urinary hepcidin in congenital chronic anemias","volume":"48","author":"Kearney","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2020022011594555600_B43","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood-2014-10-606491","article-title":"Hepcidin is suppressed by erythropoiesis in hemoglobin E \u03b2-thalassemia and \u03b2-thalassemia trait","volume":"125","author":"Jones","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2020022011594555600_B44","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMcibr1304338","article-title":"Treating iron overload","volume":"368","author":"Camaschella","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2020022011594555600_B45","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.hoc.2010.08.003","article-title":"Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in \u03b2-thalassemia","volume":"24","author":"Gardenghi","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2020022011594555600_B46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s42255-018-0005-8","article-title":"Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signaling","volume":"1","author":"Rauner","year":"2019","journal-title":"Nat Metab"},{"issue":"1","key":"2020022011594555600_B47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00264-014-2550-4","article-title":"Exogenous BMP7 corrects plasma iron overload and bone loss in Bmp6-\/- mice","volume":"39","author":"Pauk","year":"2015","journal-title":"Int Orthop"},{"issue":"12","key":"2020022011594555600_B48","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/s41366-019-0421-1","article-title":"Bone morphogenetic protein 2 is a depot-specific regulator of human adipogenesis","volume":"43","author":"Denton","year":"2019","journal-title":"Int J Obes (Lond)"},{"issue":"suppl 1","key":"2020022011594555600_B49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2019-125822","article-title":"Erythroferrone regulates bone remodeling in beta-thalassemia","volume":"134","author":"Castro-Mollo","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2020022011594555600_B50","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1629","article-title":"High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin","volume":"13","author":"Tanno","year":"2007","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/8\/547\/1716823\/bloodbld2019003140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/8\/547\/1716823\/bloodbld2019003140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T18:41:14Z","timestamp":1722278474000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/8\/547\/430059\/Antibodies-against-the-erythroferrone-Nterminal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,2,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003140","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]}}}